Free Trial

PharmaCyte Biotech Q3 2024 Earnings Report

PharmaCyte Biotech logo
$1.64 0.00 (0.00%)
(As of 12/20/2024 05:16 PM ET)

PharmaCyte Biotech EPS Results

Actual EPS
-$0.65
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

PharmaCyte Biotech Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

PharmaCyte Biotech Announcement Details

Quarter
Q3 2024
Time
N/A

Conference Call Resources

Did You See Trump’s Bombshell Exec. Order 001? (Ad)

Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minutes of stepping into the Oval Office...

I put all the details together for you here — but please hurry. 

PharmaCyte Biotech Earnings Headlines

The #1 Coin for November 2024
Grayscale Investments just announced a new fund offering access to a HOT new DeFi coin… And thanks to this newly established trust, I believe this coin could skyrocket up to 150x+ in the next 30 days alone! I've compiled everything you need to know about this once-in-a-lifetime DeFi project into a brand-new comprehensive guide…
See More PharmaCyte Biotech Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like PharmaCyte Biotech? Sign up for Earnings360's daily newsletter to receive timely earnings updates on PharmaCyte Biotech and other key companies, straight to your email.

About PharmaCyte Biotech

PharmaCyte Biotech (NASDAQ:PMCB), a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. The company develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; and license agreements with SG Austria Pte. Ltd. and Austrianova Singapore Pte. Ltd. to use the Cell-in-the-Box technology for cancer treatment. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.

View PharmaCyte Biotech Profile

More Earnings Resources from MarketBeat

Upcoming Earnings